Because the reduced expression of Sgt1 protein that resulted from Sgt1 heterozygous knockout suppressed Hras-mediated transformation and tumorigenicity of p53−/− MEF cells and prolonged the survival of p53−/− mice (Figure 2), we hypothesized that Sgt1 is a potential target for cancer therapy. The gene discussed is TP53; the disease is cancer.